Review of hemoglobin-vesicles as artificial oxygen carriers

Hiromi Sakai, Keitaro Sou, Hirohisa Horinouchi, Koichi Kobayashi, Eishun Tsuchida

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: infection, blood type mismatching, immunological response, short shelf life, and screening test costs. Blood substitutes have been under development for decades to overcome such problems. Plasma component substitutes have already been established: plasma expanders, electrolytes, and recombinant coagulant factors. Herein, we focus on the development of red blood cell (RBC) substitutes. Side effects hindered early development of cell-free hemoglobin (Hb)-based oxygen carriers (HBOCs) and underscored the physiological importance of the cellular structure of RBCs. Well-designed artificial oxygen carriers that meet requisite criteria are expected to be realized eventually. Encapsulation of Hb is one idea to shield the toxicities of molecular Hbs. However, intrinsic issues of encapsulated Hbs must be resolved: difficulties related to regulating the molecular assembly, and management of its physicochemical and biochemical properties. Hb-vesicles (HbV) are a cellular type of HBOC that overcome these issues. The in vivo safety and efficacy of HbV have been studied extensively. The results illustrate the potential of HbV as a transfusion alternative and promise its use for other clinical applications that remain unattainable using RBC transfusion.

Original languageEnglish
Pages (from-to)139-145
Number of pages7
JournalArtificial Organs
Volume33
Issue number2
DOIs
Publication statusPublished - 2009 Feb

Fingerprint

Blood Substitutes
Hemoglobin
Hemoglobins
Blood
Oxygen
Plasma Substitutes
Erythrocyte Transfusion
Coagulants
Blood substitutes
Cellular Structures
Plasmas
Blood Transfusion
Electrolytes
Erythrocytes
Encapsulation
Toxicity
Safety
Costs and Cost Analysis
Screening
Cells

Keywords

  • Blood substitutes
  • Hemoglobin
  • Liposome
  • Perfusion
  • Transfusion

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Bioengineering
  • Medicine (miscellaneous)

Cite this

Sakai, H., Sou, K., Horinouchi, H., Kobayashi, K., & Tsuchida, E. (2009). Review of hemoglobin-vesicles as artificial oxygen carriers. Artificial Organs, 33(2), 139-145. https://doi.org/10.1111/j.1525-1594.2008.00698.x

Review of hemoglobin-vesicles as artificial oxygen carriers. / Sakai, Hiromi; Sou, Keitaro; Horinouchi, Hirohisa; Kobayashi, Koichi; Tsuchida, Eishun.

In: Artificial Organs, Vol. 33, No. 2, 02.2009, p. 139-145.

Research output: Contribution to journalArticle

Sakai, H, Sou, K, Horinouchi, H, Kobayashi, K & Tsuchida, E 2009, 'Review of hemoglobin-vesicles as artificial oxygen carriers', Artificial Organs, vol. 33, no. 2, pp. 139-145. https://doi.org/10.1111/j.1525-1594.2008.00698.x
Sakai H, Sou K, Horinouchi H, Kobayashi K, Tsuchida E. Review of hemoglobin-vesicles as artificial oxygen carriers. Artificial Organs. 2009 Feb;33(2):139-145. https://doi.org/10.1111/j.1525-1594.2008.00698.x
Sakai, Hiromi ; Sou, Keitaro ; Horinouchi, Hirohisa ; Kobayashi, Koichi ; Tsuchida, Eishun. / Review of hemoglobin-vesicles as artificial oxygen carriers. In: Artificial Organs. 2009 ; Vol. 33, No. 2. pp. 139-145.
@article{6a06f61013554b66b035badab4b914ff,
title = "Review of hemoglobin-vesicles as artificial oxygen carriers",
abstract = "Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: infection, blood type mismatching, immunological response, short shelf life, and screening test costs. Blood substitutes have been under development for decades to overcome such problems. Plasma component substitutes have already been established: plasma expanders, electrolytes, and recombinant coagulant factors. Herein, we focus on the development of red blood cell (RBC) substitutes. Side effects hindered early development of cell-free hemoglobin (Hb)-based oxygen carriers (HBOCs) and underscored the physiological importance of the cellular structure of RBCs. Well-designed artificial oxygen carriers that meet requisite criteria are expected to be realized eventually. Encapsulation of Hb is one idea to shield the toxicities of molecular Hbs. However, intrinsic issues of encapsulated Hbs must be resolved: difficulties related to regulating the molecular assembly, and management of its physicochemical and biochemical properties. Hb-vesicles (HbV) are a cellular type of HBOC that overcome these issues. The in vivo safety and efficacy of HbV have been studied extensively. The results illustrate the potential of HbV as a transfusion alternative and promise its use for other clinical applications that remain unattainable using RBC transfusion.",
keywords = "Blood substitutes, Hemoglobin, Liposome, Perfusion, Transfusion",
author = "Hiromi Sakai and Keitaro Sou and Hirohisa Horinouchi and Koichi Kobayashi and Eishun Tsuchida",
year = "2009",
month = "2",
doi = "10.1111/j.1525-1594.2008.00698.x",
language = "English",
volume = "33",
pages = "139--145",
journal = "Artificial Organs",
issn = "0160-564X",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Review of hemoglobin-vesicles as artificial oxygen carriers

AU - Sakai, Hiromi

AU - Sou, Keitaro

AU - Horinouchi, Hirohisa

AU - Kobayashi, Koichi

AU - Tsuchida, Eishun

PY - 2009/2

Y1 - 2009/2

N2 - Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: infection, blood type mismatching, immunological response, short shelf life, and screening test costs. Blood substitutes have been under development for decades to overcome such problems. Plasma component substitutes have already been established: plasma expanders, electrolytes, and recombinant coagulant factors. Herein, we focus on the development of red blood cell (RBC) substitutes. Side effects hindered early development of cell-free hemoglobin (Hb)-based oxygen carriers (HBOCs) and underscored the physiological importance of the cellular structure of RBCs. Well-designed artificial oxygen carriers that meet requisite criteria are expected to be realized eventually. Encapsulation of Hb is one idea to shield the toxicities of molecular Hbs. However, intrinsic issues of encapsulated Hbs must be resolved: difficulties related to regulating the molecular assembly, and management of its physicochemical and biochemical properties. Hb-vesicles (HbV) are a cellular type of HBOC that overcome these issues. The in vivo safety and efficacy of HbV have been studied extensively. The results illustrate the potential of HbV as a transfusion alternative and promise its use for other clinical applications that remain unattainable using RBC transfusion.

AB - Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: infection, blood type mismatching, immunological response, short shelf life, and screening test costs. Blood substitutes have been under development for decades to overcome such problems. Plasma component substitutes have already been established: plasma expanders, electrolytes, and recombinant coagulant factors. Herein, we focus on the development of red blood cell (RBC) substitutes. Side effects hindered early development of cell-free hemoglobin (Hb)-based oxygen carriers (HBOCs) and underscored the physiological importance of the cellular structure of RBCs. Well-designed artificial oxygen carriers that meet requisite criteria are expected to be realized eventually. Encapsulation of Hb is one idea to shield the toxicities of molecular Hbs. However, intrinsic issues of encapsulated Hbs must be resolved: difficulties related to regulating the molecular assembly, and management of its physicochemical and biochemical properties. Hb-vesicles (HbV) are a cellular type of HBOC that overcome these issues. The in vivo safety and efficacy of HbV have been studied extensively. The results illustrate the potential of HbV as a transfusion alternative and promise its use for other clinical applications that remain unattainable using RBC transfusion.

KW - Blood substitutes

KW - Hemoglobin

KW - Liposome

KW - Perfusion

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=57749208685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749208685&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1594.2008.00698.x

DO - 10.1111/j.1525-1594.2008.00698.x

M3 - Article

VL - 33

SP - 139

EP - 145

JO - Artificial Organs

JF - Artificial Organs

SN - 0160-564X

IS - 2

ER -